| Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.Clin Cancer Res | PMID 35552673PMC9662922 | 2022-Aug-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.Cancer | PMID 35727053PMC11497250 | 2022-Aug-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial.Vaccine | PMID 35810063无 PMCID | 2022-Aug-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.Blood Adv | PMID 35594559PMC9636327 | 2022-Aug-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.J Natl Cancer Inst | PMID 35512402PMC9360461 | 2022-Aug-08 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis.Arthritis Res Ther | PMID 35941676PMC9358905 | 2022-Aug-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.Lancet | PMID 35934006无 PMCID | 2022-Aug-06 | 0.85 | The record meets criteria for oncology, human, randomized, Phase III, and time-to-event efficacy endpoint. However, it does not include a drug-containing intervention; the study compares radiation dose and fractionation schedules (radiation therapy) with or without a tumor bed boost, which is a radiation-based intervention, not a drug. The inclusion criteria require a drug-containing intervention. | 待处理 |
| A randomized controlled trial comparing perioperative vs. postoperative mFOLFOX6 for lower rectal cancer with suspected lateral pelvic lymph node metastasis (JCOG1310): a phase II/III randomized controlled trial.Jpn J Clin Oncol | PMID 35640246PMC9354501 | 2022-Aug-05 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| 2-deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial.BMC Infect Dis | PMID 35927676PMC9351257 | 2022-Aug-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.J Am Heart Assoc | PMID 35916348PMC9375471 | 2022-Aug-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).J Clin Oncol | PMID 35298280PMC7614664 | 2022-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer.Int J Gynecol Cancer | PMID 35321888无 PMCID | 2022-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.J Acquir Immune Defic Syndr | PMID 35344520PMC9342948 | 2022-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.J Clin Oncol | PMID 35394800PMC9467680 | 2022-Aug-01 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.J Clin Oncol | PMID 35404684无 PMCID | 2022-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).Int J Cancer | PMID 35411939PMC9321995 | 2022-Aug-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Radiation Therapy Dose Escalation in Unresectable Ewing Sarcoma: Final Results of a Phase 3 Randomized Controlled Trial.Int J Radiat Oncol Biol Phys | PMID 35568246无 PMCID | 2022-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.JAMA Oncol | PMID 35653145PMC9164117 | 2022-Aug-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.J Clin Rheumatol | PMID 35653615PMC9336574 | 2022-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.JAMA Ophthalmol | PMID 35708706PMC9204622 | 2022-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.J Clin Oncol | PMID 35709465无 PMCID | 2022-Aug-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial.JAMA Dermatol | PMID 35830173PMC9280611 | 2022-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Acceptability of Telerehabilitation for Magnification Devices for the Visually Impaired Using Various Approaches to Facilitate Accessibility.Transl Vis Sci Technol | PMID 35917136PMC9358294 | 2022-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.JAMA Netw Open | PMID 35997978PMC9399878 | 2022-Aug-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.Clin Gastroenterol Hepatol | PMID 33127596无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA).Br J Ophthalmol | PMID 33712478PMC9340030 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma: post hoc pooled analysis from PALLADIUM and IRIDIUM studies.J Asthma | PMID 34346266无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients.Pharm Res | PMID 35233731PMC9314306 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.Allergy | PMID 35266148PMC9356972 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial.J Rheumatol | PMID 35428718无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).J Am Acad Dermatol | PMID 35439608无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab | PMID 35441470PMC9542252 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.J Bone Miner Res | PMID 35466448PMC9544335 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Randomized, Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC).Ann Surg Oncol | PMID 35524087无 PMCID | 2022-Aug | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.Epilepsia | PMID 35582748PMC9541390 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perioperative optimization with nutritional supplements in patients undergoing gastrointestinal surgery for cancer: A randomized, placebo-controlled feasibility clinical trial.Surgery | PMID 35606184无 PMCID | 2022-Aug | 0.85 | The study is a randomized, placebo-controlled pilot/feasibility trial in human oncology patients. However, it fails inclusion due to: 1) The intervention is nutritional supplements (non-drug), not a drug-containing intervention. 2) It is a Phase II/feasibility study, not a definitive Phase III trial. 3) The primary endpoint is enrollment feasibility, and secondary endpoints include compliance and postoperative complications (not time-to-event efficacy like OS, PFS, DFS). No Kaplan-Meier or HR is reported for an efficacy endpoint. | 待处理 |
| A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.Bone Marrow Transplant | PMID 35610308PMC9352570 | 2022-Aug | 0.95 | Meets all eligibility criteria: Phase III randomized oncology trial in humans with a drug intervention and primary/key secondary time-to-event efficacy endpoint (PFS). | 待处理 |
| Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.Am J Hematol | PMID 35617104无 PMCID | 2022-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of PavéDerm J-Fill for nasolabial folds: A phase III randomized, blinded, prospective, and split-faced head-to-head trial.Dermatol Ther | PMID 35642570无 PMCID | 2022-Aug | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Comparison of ciprofol (HSK3486) versus propofol for the induction of deep sedation during gastroscopy and colonoscopy procedures: A multi-centre, non-inferiority, randomized, controlled phase 3 clinical trial.Basic Clin Pharmacol Toxicol | PMID 35653554PMC9543620 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.Lancet Respir Med | PMID 35662406无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials.Breast | PMID 35691249PMC9190051 | 2022-Aug | 0.90 | Study is a Phase II, single-arm trial investigating radiotherapy (non-drug intervention), not a randomized Phase III trial with a drug-containing intervention. | 待处理 |
| Ovarian reserve in premenopausal women with breast cancer.Breast | PMID 35691250PMC9194452 | 2022-Aug | 0.85 | The record is from a definitive phase III randomized oncology trial, but it reports on ovarian reserve biomarker changes (AMH), not the required survival, progression, recurrence, death, or time-to-event efficacy outcomes. | 待处理 |
| Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study.Fertil Steril | PMID 35710599无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.Adv Ther | PMID 35716319PMC9309120 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial.Lancet Haematol | PMID 35777413无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.Lancet Haematol | PMID 35779558PMC9243568 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.Lancet Haematol | PMID 35779560PMC9243570 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life.ESMO Open | PMID 35785595PMC9434166 | 2022-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 35798016无 PMCID | 2022-Aug | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |